TY - JOUR T1 - The study of using Rhenium-188 liposomal drug and 5-FU in chemoradiotherapy to suppress tumor growth in head and neck squamous cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1459 LP - 1459 VL - 57 IS - supplement 2 AU - Chun-Yuan Chang AU - Yuan Heng Tu AU - Te-Wei Lee AU - Chih-Hsien Chang AU - Hsin-Ell Wang AU - Ren-Shyan Liu AU - Yi-Jang Lee Y1 - 2016/05/01 UR - http://jnm.snmjournals.org/content/57/supplement_2/1459.abstract N2 - 1459Objectives Head and neck squamous cell carcinoma (HNSCC) is ranked as top four of Taiwanese malignant tumor incidence in recent statistical analysis. Recently, the PEGylated liposomal drugs have been developed for a better accumulation and resident time in tumor location. In this study, we used rhenium-188 (188Re) who emits therapeutic β -particles and detectable γ -rays, for enhancing therapeutic efficacy through radiotherapy in short distance to treat HNSCC. However, 188 Re-liposomal drug only suppressed the tumor growth temporarily. Therefore, it is essential for knowing whether using Rhenium-188 liposomal drug combining chemotherapeutic agent could be a potential therapeutic strategies.Methods In this study, we evaluated the therapeutic effects of single dose 188Re-liposomal drug combining chemotherapeutic drugs 5-fluorouracil (5-FU) on HNSCC using small animal model. HNSCC cell line has harbored luciferase gene and herpse virus type 1-thymidine kinase genes for optical imaging and radionuclide-based imaging, respectively.Results We demonstrated 188Re-liposome radiopharmaceutic in hypopharyngeal carcinoma by an overall evaluation of pharmacokinetic and internal dosimetry. The result indicated that 188 Re-liposome only temporarily suppressed the growth of HNSCC for 2 weeks which suggests that single dose may not sufficient to long-term inhibit tumor growth. Therefore, the efficacy of single dose treatment combining chemotherapeutic agents was performed to enhance the effects of 188Re-liposome on long-term tumor suppression. Interestingly, inhibitory effect of tumor growth was found in combine treatment group.Conclusions In this study, we demonstrated the bio-distribution, pharmacokinetics, and the therapeutic efficacy from the treatment of 188Re-embedded PEGylated liposome. Based most update results, HNSCC can only be suppressed by a period of time, while using dose 188Re-liposome combining chemotherapeutic drugs 5-fluorouracil (5-FU) is able to suppress tumor growth, which may provide essential information for future application of the 188Re-liposome on clinical cancer therapy. ER -